{"name": "Kala Pharmaceuticals",
 "permalink": "kala-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/kala-pharmaceuticals",
 "homepage_url": "http://www.kalarx.com",
 "blog_url": "",
 "blog_feed_url": "http://www.kalarx.com/news-press-releases.php",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2009,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@kalarx.com",
 "phone_number": "617-542-2241",
 "description": "Healthcare ",
 "created_at": "Sat Dec 26 02:21:28 UTC 2009",
 "updated_at": "Wed Mar 27 09:02:41 UTC 2013",
 "overview": "\u003Cp\u003EKala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company\u0026#8217;s proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala\u0026#8217;s formulations achieve high, sustained local drug concentrations with reduced systemic exposure and are delivered in a patient friendly format. The company\u0026#8217;s research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept, while establishing R\u0026amp;D collaborations with select partners to improve products in their pipelines.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       66],
      "assets/images/resized/0017/8187/178187v1-max-150x150.jpg"],
     [[250,
       110],
      "assets/images/resized/0017/8187/178187v1-max-250x250.jpg"],
     [[253,
       112],
      "assets/images/resized/0017/8187/178187v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "Rob",
      "last_name": "Paull",
      "permalink": "rob-paull",
      "image": null}},
   {"is_past": false,
    "title": "CEO and Director",
    "person":
     {"first_name": "Mr.",
      "last_name": "Robert Paull",
      "permalink": "mr-robert-paull",
      "image": null}},
   {"is_past": false,
    "title": "Vice President, Research",
    "person":
     {"first_name": "Hongming",
      "last_name": "Chen",
      "permalink": "hongming-chen",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$22.7M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "http://www.masshightech.com/stories/2009/12/21/daily38-Stealthy-Kala-Pharmaceuticals-lands-2M.html",
    "source_description": "Stealthy Kala Pharmaceuticals lands $2M",
    "raised_amount": 2000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 12,
    "funded_day": 24,
    "investments":
     []},
   {"round_code": "b",
    "source_url": "http://www.masshightech.com/stories/2010/11/08/daily35-Kala-Pharmaceuticals-collects-3M-in-new-funds.html",
    "source_description": "Kala Pharmaceuticals collects $3M in new funds",
    "raised_amount": 3000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 11,
    "funded_day": 10,
    "investments":
     []},
   {"round_code": "unattributed",
    "source_url": "http://www.finsmes.com/2012/03/kala-pharmaceuticals-raises-6-2m-equity-financing.html?utm_source=feedburner\u0026utm_medium=feed\u0026utm_campaign=Feed%3A+finsmes%2FcNHu+%28FinSMEs%29",
    "source_description": "Kala Pharmaceuticals Raises $6.2M in Equity Financing",
    "raised_amount": 6200000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 3,
    "funded_day": 14,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Lux Capital",
         "permalink": "lux-capital",
         "image":
          {"available_sizes":
            [[[150,
               54],
              "assets/images/resized/0004/3976/43976v1-max-150x150.png"],
             [[250,
               90],
              "assets/images/resized/0004/3976/43976v1-max-250x250.png"],
             [[261,
               94],
              "assets/images/resized/0004/3976/43976v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Polaris Partners",
         "permalink": "polaris-partners",
         "image":
          {"available_sizes":
            [[[150,
               36],
              "assets/images/resized/0001/1153/11153v1-max-150x150.png"],
             [[163,
               40],
              "assets/images/resized/0001/1153/11153v1-max-250x250.png"],
             [[163,
               40],
              "assets/images/resized/0001/1153/11153v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Third Rock Ventures",
         "permalink": "third-rock-ventures-2",
         "image":
          {"available_sizes":
            [[[150,
               78],
              "assets/images/resized/0005/0700/50700v1-max-150x150.png"],
             [[205,
               107],
              "assets/images/resized/0005/0700/50700v1-max-250x250.png"],
             [[205,
               107],
              "assets/images/resized/0005/0700/50700v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Lighthouse Capital Partners",
         "permalink": "lighthouse-capital-partners",
         "image":
          {"available_sizes":
            [[[150,
               62],
              "assets/images/resized/0002/9753/29753v1-max-150x150.jpg"],
             [[199,
               83],
              "assets/images/resized/0002/9753/29753v1-max-250x250.jpg"],
             [[199,
               83],
              "assets/images/resized/0002/9753/29753v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "a",
    "source_url": "http://www.finsmes.com/2013/02/kala-pharmaceuticals-raises-11-5m-series-equity-financing.html",
    "source_description": "Kala Pharmaceuticals Raises $11.5M in Series A Equity Financing",
    "raised_amount": 11500000.0,
    "raised_currency_code": "USD",
    "funded_year": 2013,
    "funded_month": 2,
    "funded_day": 28,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Lux Capital",
         "permalink": "lux-capital",
         "image":
          {"available_sizes":
            [[[150,
               54],
              "assets/images/resized/0004/3976/43976v1-max-150x150.png"],
             [[250,
               90],
              "assets/images/resized/0004/3976/43976v1-max-250x250.png"],
             [[261,
               94],
              "assets/images/resized/0004/3976/43976v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Polaris Partners",
         "permalink": "polaris-partners",
         "image":
          {"available_sizes":
            [[[150,
               36],
              "assets/images/resized/0001/1153/11153v1-max-150x150.png"],
             [[163,
               40],
              "assets/images/resized/0001/1153/11153v1-max-250x250.png"],
             [[163,
               40],
              "assets/images/resized/0001/1153/11153v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Third Rock Ventures",
         "permalink": "third-rock-ventures-2",
         "image":
          {"available_sizes":
            [[[150,
               78],
              "assets/images/resized/0005/0700/50700v1-max-150x150.png"],
             [[205,
               107],
              "assets/images/resized/0005/0700/50700v1-max-250x250.png"],
             [[205,
               107],
              "assets/images/resized/0005/0700/50700v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Crown Venture Fund",
         "permalink": "crown-venture-fund",
         "image": null},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "135 Beaver St., Suite 309",
    "address2": "",
    "zip_code": "02452",
    "city": "Waltham",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        89],
       "assets/images/resized/0017/8188/178188v1-max-150x150.jpg"],
      [[250,
        149],
       "assets/images/resized/0017/8188/178188v1-max-250x250.jpg"],
      [[450,
        269],
       "assets/images/resized/0017/8188/178188v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}